Shares of TapImmune Inc. (NASDAQ:MRKR) have been assigned an average recommendation of “Buy” from the eight analysts that are covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. The average 1 year price target among analysts that have issued a report on the stock in the last year is $10.72.
A number of research firms have recently commented on MRKR. Janney Montgomery Scott cut their target price on TapImmune from $15.00 to $10.00 and set a “buy” rating on the stock in a research report on Wednesday, November 13th. Zacks Investment Research downgraded TapImmune from a “hold” rating to a “sell” rating in a research note on Thursday, October 10th. ValuEngine raised TapImmune from a “hold” rating to a “buy” rating in a research report on Wednesday, October 2nd. Piper Jaffray Companies decreased their price objective on TapImmune from $10.00 to $6.00 and set an “overweight” rating for the company in a report on Wednesday, November 13th. Finally, Nomura reissued a “buy” rating and issued a $16.00 price objective on shares of TapImmune in a report on Tuesday, August 13th.
Shares of TapImmune stock opened at $3.00 on Wednesday. The firm has a market capitalization of $144.93 million, a P/E ratio of -1.80 and a beta of 0.11. The company has a quick ratio of 15.83, a current ratio of 15.83 and a debt-to-equity ratio of 0.01. TapImmune has a 52 week low of $2.61 and a 52 week high of $9.17. The firm’s 50 day moving average is $3.64 and its two-hundred day moving average is $5.35.
TapImmune Company Profile
Marker Therapeutics, Inc, a clinical-stage immuno-oncology company, develops and commercializes novel cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. Its MultiTAA T cell technology is based on the tumor-specific T cells that recognize tumor associated antigens and kill tumor cells expressing those targets.
Featured Story: Return on Investment (ROI) Defined, Explained
Receive News & Ratings for TapImmune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TapImmune and related companies with MarketBeat.com's FREE daily email newsletter.